Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthSpring Avacincaptad Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedHealthSpringPolicy OTH903.045

    Avacincaptad pegol

    Customize your policy alerts

    Sign up for healthspring Policy OTH903.045 alerts

    Get alerted when Policy OTH903.045 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage review for avacincaptad pegol, subject to the member’s benefit plan, applicable state regulations, FDA-approved labeling, recognized clinical evidence, and an Ohio-specific exception for certain recognized off-label uses.

    Policy Summary
    PayerHealthSpring
    PolicyAvacincaptad pegol
    Policy CodePolicy OTH903.045
    Change TypeNew policy
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionDocument a confirmed diagnosis of geographic atrophy secondary to age-related macular degeneration and the absence of ocular or periocular infection or active intraocular inflammation.
    SourceLink
    POLICY UPDATE CHANGES

    A new medical policy establishes medical-necessity criteria for avacincaptad pegol (Izervay) in adults with geographic atrophy secondary to age-related macular degeneration.

    OhioState-specific exception
    2Peer-reviewed articles for Ohio off-label support
    2Medical-necessity criteria
    AdultsCovered population
    Monthly

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Administration frequency

    Coverage Criteria

    Ohio Off-Label Coverage Exception

    For Ohio members, coverage of an FDA-approved drug prescribed for an off-label use is required when ALL of the following criteria are met:

    ALL of the following

    • The individual resides in Ohio and the applicable group or individual policy covers prescription drugs.
    • The drug is approved by the U.S. Food and Drug Administration (FDA).
    • The prescribed use is recognized as safe and effective for treatment of the indication in one or more standard medical reference compendia adopted by the U.S. Department of Health and Human Services, or in medical literature.
    • ONE of the following supports the off-label use

      • The use is recognized in an applicable standard medical reference compendium adopted by the U.S. Department of Health and Human Services.
      • Safety and efficacy are confirmed in two articles from major peer-reviewed professional medical journals that present data supporting the proposed off-label use as generally safe and effective.

        Examples of accepted journals include JAMA, NEJM, and Lancet. Accepted study designs may include randomized, double-blind, placebo-controlled clinical trials. Case studies and case series alone are insufficient.

    Initial Medical Necessity

    Avacincaptad pegol (Izervay™) may be considered medically necessary in adults when ALL of the following criteria are met:

    ALL of the following

    • The individual is an adult.
    • The individual has a confirmed diagnosis of geographic atrophy secondary to age-related macular degeneration (AMD).
    • The individual does not have any ocular or periocular infection or active intraocular inflammation.

    Initial Therapy

    Initial therapy with avacincaptad pegol (Izervay™) may be considered medically necessary when the Initial Medical Necessity criteria above are met.

    ALL of the following

    • The individual is an adult with a confirmed diagnosis of geographic atrophy secondary to AMD.
    • The individual does not have any ocular or periocular infection or active intraocular inflammation.

    Unproven or Non-FDA-Approved Indications

    Avacincaptad pegol (Izervay) is considered experimental, investigational and/or unproven for all other non-U.S. Food and Drug Administration-approved indications.

    Any indication other than geographic atrophy secondary to age-related macular degeneration is considered experimental, investigational and/or unproven when it is not approved by the FDA.

    For Ohio members, coverage is never required when the FDA has recognized the use as contraindicated. Coverage is also not required for non-formulary drugs.

    Coverage is limited to FDA-approved indications and is not provided for non-FDA-approved indications except where an applicable state-mandated off-label coverage exception applies.

    Uses of avacincaptad pegol (Izervay) that are not approved by the FDA are not covered under the medically necessary indication described in this policy.

    Avacincaptad pegol (Izervay) is considered experimental, investigational and/or unproven for all other non-U.S. Food and Drug Administration-approved indications.

    Coding

    CPT CodesCPT
    67028CPT Codes 67028
    HCPCS CodesHCPCS
    J2782HCPCS Codes J2782

    Provider Actions and Review Considerations

    Prior Authorization

    Confirm Diagnosis and Ocular Eligibility

    For prior authorization, submit documentation confirming the member is an adult with geographic atrophy secondary to age-related macular degeneration (AMD) and does not have ocular or periocular infection or active intraocular inflammation.

    • Confirmed diagnosis of geographic atrophy secondary to AMD
    • Adult patient eligibility
    • No ocular/periocular infection or active intraocular inflammation
    Prior Authorization

    Specialist Prescribing and FDA-Labeled Dosing

    Avacincaptad pegol (Izervay) should be prescribed by or in consultation with an ophthalmologist experienced in treating retinal diseases. Administration must follow U.S. FDA-approved labeling: intravitreal injection in each affected eye once monthly, approximately every 28 ± 7 days.

    • Ophthalmologist prescribing or consultation is required
    • Use FDA-labeled dosing and administration

    Background

    Coverage of avacincaptad pegol is evaluated using FDA-approved labeling and nationally recognized authoritative references, including recognized drug compendia, peer-reviewed literature, professional society guidelines, and applicable CMS coverage policy. Providers and members should also review the applicable benefit plan or contract because contractual exclusions and limitations govern when they differ from the medical policy.

    Definitions

    Geographic Atrophy
    DefinitionAn advanced form of dry age-related macular degeneration characterized by atrophic lesions that begin in the outer retina and progressively expand to cover the macula.
    Vision impactProgressive geographic atrophy can lead to irreversible loss of vision over time.
    Disease processAtrophic lesions may progressively grow to involve the fovea, severely impairing central vision.
    Avacincaptad Pegol
    Drug classComplement C5 protein inhibitor.
    MechanismBlocks the activity of complement protein C5.
    Clinical effect

    Initial Therapy Criteria

    Initial Treatment

    Avacincaptad pegol may be considered medically necessary in adults when all of the following are met:

    Initial treatment criteria

    • Diagnosis: The individual has a confirmed diagnosis of geographic atrophy secondary to age-related macular degeneration (AMD).
    • Ocular safety eligibility: The individual does not have any ocular or periocular infection or active intraocular inflammation.

    Initial Izervay Coverage

    Coverage may be considered medically necessary for adults when all criteria are met.

    Izervay initial therapy

    Quantity Limits and Administration

    Quantity Limits
    MedicationIzervay (avacincaptad pegol).
    AdministrationOne intravitreal injection to each affected eye.
    FrequencyOnce monthly, approximately every 28 ± 7 days.
    Policy Summary
    PayerHealthSpring
    PolicyAvacincaptad pegol
    Policy CodePolicy OTH903.045
    Change TypeNew policy
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionDocument a confirmed diagnosis of geographic atrophy secondary to age-related macular degeneration and the absence of ocular or periocular infection or active intraocular inflammation.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions and Review ConsiderationsBackgroundDefinitionsInitial Therapy CriteriaQuantity Limits and Administration
  1. Monitor for neovascular AMD, endophthalmitis, retinal detachment, and increased intraocular pressure
  2. Documentation Required

    Medical-Necessity Criteria

    Izervay may be considered medically necessary for adults when the required diagnosis and exclusion criteria are documented.

    • Confirmed geographic atrophy secondary to AMD
    • No ocular or periocular infection
    • No active intraocular inflammation
    Note

    Ohio Off-Label Evidence Requirements

    For members residing in Ohio, coverage of an FDA-approved drug for an off-label use may be required when the use is recognized as safe and effective in an adopted standard medical compendium or supported by medical literature. Medical-literature support requires safety and efficacy confirmation in two articles from major peer-reviewed professional medical journals; case studies or case series alone are insufficient.

    • Applicable to covered Ohio group or individual policies
    • Two major peer-reviewed medical-journal articles must support the proposed off-label use
    • Coverage is not required for FDA-recognized contraindications or non-formulary drugs
    Documentation Required

    Required Clinical Documentation

    The clinical record and prior-authorization submission must establish the diagnosis, adult eligibility, and absence of exclusionary ocular conditions before treatment is authorized.

    • Document geographic atrophy secondary to AMD
    • Document that the patient is an adult
    • Document absence of ocular/periocular infection and active intraocular inflammation
    • Include relevant ophthalmology evaluation and treatment plan

    Unsupported block type: denial_risk לפcallout

    Denial Risk

    Non-FDA-Approved Indication

    Requests for avacincaptad pegol (Izervay) for indications other than the FDA-approved treatment of geographic atrophy secondary to AMD are considered experimental, investigational, and/or unproven.

    • FDA-approved indication: geographic atrophy secondary to AMD
    • Other indications are not medically necessary under this policy
    Denial Risk

    Active Ocular Infection or Inflammation

    Do not administer Izervay when the patient has an ocular or periocular infection or active intraocular inflammation. These conditions are an exclusion to medical necessity and a denial risk.

    • Ocular infection
    • Periocular infection
    • Active intraocular inflammation
    Denial Risk

    Contraindicated Ocular Conditions

    Izervay is contraindicated in individuals with ocular or periocular infections and in individuals with active intraocular inflammation. Verify that these conditions are absent before each treatment decision and document the assessment.

    • Do not treat in the presence of ocular infection
    • Do not treat in the presence of periocular infection
    • Do not treat with active intraocular inflammation
    Denial Risk

    Pediatric Use Not Established

    The safety and effectiveness of Izervay in pediatric patients have not been established. Coverage and treatment requests should therefore be evaluated against the policy’s adult eligibility requirement.

    • Pediatric safety and effectiveness are not established
    • Policy medical-necessity criteria apply to adults
    Denial Risk

    Non-FDA-Approved Indication

    Izervay is considered experimental, investigational, and/or unproven when requested for any indication other than geographic atrophy secondary to AMD, the FDA-approved indication.

    • Confirm the requested indication is geographic atrophy secondary to AMD
    • Deny requests for other non-FDA-approved indications
    Denial Risk

    Active Ocular Infection or Inflammation

    Requests must document that the patient does not have ocular or periocular infection or active intraocular inflammation. Treatment is not medically necessary when either exclusion is present.

    • Document absence of ocular infection
    • Document absence of periocular infection
    • Document absence of active intraocular inflammation
    By reducing activity of the complement cascade that damages the retina, avacincaptad pegol has the potential to slow progression of geographic atrophy.
    Diagnosis: The individual is an adult with a confirmed diagnosis of geographic atrophy secondary to age-related macular degeneration.
  3. Absence of active ocular conditions: The individual does not have any ocular or periocular infection or active intraocular inflammation.